Vaccines for suppressing ige-mediated allergic disease and methods for using the same

Abstract

Nucleic acid molecules that encode a protein comprising at least one epitope of membrane IgE free of epitopes present on the serum IgE, including proteins that further comprise non-IgE T cell helper epitope are disclosed. Vaccines, vectors and host cells that comprise such nucleic acid molecules are disclosed. Isolated proteins, including haptenized proteins, comprising at least one epitope of membrane IgE free of epitopes present on the serum IgE, including proteins that further comprise non-IgE T cell helper epitope are disclosed. Vaccines that comprise and methods of making such proteins and antibodies that specifically bind to such proteins are disclosed. Killed or inactivated cells or particles, including haptenized killed or inactivated cells or particles, that comprise a protein comprising at least one epitope of membrane IgE free of epitopes present on the serum IgE, including proteins that further comprise non-IgE T cell helper epitope are disclosed. Vaccines that comprise such killed or inactivated cells or particles are disclosed. Methods of treating and preventing IgE mediated allergic disease or condition are disclosed.

1 . An isolated nucleic acid molecule that encodes protein comprising at least one epitope of membrane IgE and being free of epitopes of serum IgE.  
     
     
         2 . The nucleic acid molecule of  claim 1  wherein said protein is membrane IgE or a fragment thereof.  
     
     
         3 . The nucleic acid molecule of  claim 2  wherein said protein is membrane IgE.  
     
     
         4 . The nucleic acid molecule of  claim 1  further comprising coding sequence encoding of at least one non-IgE helper T cell epitope.  
     
     
         5 . The nucleic acid molecule of  claim 4  wherein the coding sequence encoding of at least one non-IgE helper T cell epitope encodes tetanus toxoid Th epitope.  
     
     
         6 . The nucleic acid molecule of  claim 2  wherein said nucleic acid molecule is a plasmid.  
     
     
         7 . The isolated nucleic acid molecule of  claim 2  wherein said nucleic acid molecule is incorporated in a viral vector or a bacterial cell.  
     
     
         8 . A vaccine composition comprising a nucleic acid molecule of  claim 1  and a pharmaceutically acceptable carrier or diluent.  
     
     
         9 . A method of treating an individual who has been identified as being susceptible to an IgE mediated allergic disease or condition comprising the step of administering to such an individual a prophylactically effective amount of a vaccine of 8.  
     
     
         10 . A method of treating an individual who has been identified as having an IgE mediated allergic disease or condition comprising the step of administering to such an individual a therapeutically effective amount of a vaccine of 8.  
     
     
         11 . An isolated protein comprising at least one epitope of membrane IgE and being free of epitopes of serum IgE.  
     
     
         12 . The isolated protein of  claim 11  wherein said protein is membrane IgE or a fragment thereof.  
     
     
         13 . The isolated protein of  claim 12  wherein said protein is membrane IgE.  
     
     
         14 . The isolated protein of  claim 11  further comprising tetanus toxoid Th epitope.  
     
     
         15 . The isolated protein of  claim 11  wherein said protein is haptenized.  
     
     
         16 . The vaccine composition comprising an isolated protein of  claim 11  and a pharmaceutically acceptable carrier or diluent.  
     
     
         17 . The vaccine composition of  claim 16  further comprising tetanus toxoid Th epitope.  
     
     
         18 . A vaccine composition comprising killed or inactivated cells or particles that comprise a protein of  claim 11  and a pharmaceutically acceptable carrier or diluent.  
     
     
         19 . The vaccine of  claim 18  wherein said killed or inactivated cells or particles are haptenized.  
     
     
         20 . A method of treating an individual who has been identified as being susceptible to an IgE mediated allergic disease or condition comprising the step of administering to such an individual a prophylactically effective amount of a vaccine of  claim 16 .  
     
     
         21 . A method of treating an individual who has been identified as having an IgE mediated allergic disease or condition comprising the step of administering to such an individual a therapeutically effective amount of a vaccine of  claim 16 .  
     
     
         22 . A host cell comprising an isolated nucleic acid molecule that encodes protein comprising at least one epitope of membrane IgE and being free of epitopes of serum IgE.  
     
     
         23 . The host cell of  claim 22  wherein said protein is membrane IgE or a fragment thereof.  
     
     
         24 . The host cell of  claim 23  wherein said protein is membrane IgE.  
     
     
         25 . The host cell of  claim 22  further comprising coding sequence encoding of at least one non-IgE helper T cell epitope.  
     
     
         26 . The host cell of  claim 25  wherein the coding sequence encoding of at least one non-IgE helper T cell epitope encodes tetanus toxoid Th epitope.  
     
     
         27 . The host cell of  claim 22  wherein said nucleic acid molecule is a plasmid.  
     
     
         28 . A method of producing a protein comprising at least one epitope of membrane IgE and being free of epitopes of serum IgE comprising culturing a host cell of  claim 22  and isolating said protein expressed thereby.  
     
     
         29 . The method of  claim 28  wherein the protein is isolated using antibodies that specifically bind to said protein.  
     
     
         30 . Antibodies that specifically bind to a protein of  claim 11 .  
     
     
         31 . The antibodies of  claim 30  wherein said antibodies are Mabs, humanized Mabs, human antibodies, or Fab or (Fab) 2  thereof